<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848783</url>
  </required_header>
  <id_info>
    <org_study_id>07-837</org_study_id>
    <secondary_id>NYU 05-20</secondary_id>
    <nct_id>NCT00848783</nct_id>
  </id_info>
  <brief_title>Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers</brief_title>
  <official_title>A Randomized Phase-II Study of Patients With Locally Advanced Gastric of Gastro-Esophageal Adenocarcinoma Treated With Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine, Followed by Prolonged Administration of Capecitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine whether intraperitoneal (IP) Floxuridine is effective in the
      patients with advanced stomach or gastro-esophageal junction cancers in the treatment
      consisting of pre- and post-surgery chemotherapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A previous Phase-II trial conducted by the same principle investigator(s), utilizing
      preoperative chemotherapy and intraperitoneal consolidation, was conducted in patients with
      locally advanced, potentially resectable gastric cancer or cancer of the gastro-esophageal
      junction (GEJ), both staged as T3N0, T4N0, any TN1 or TN2 disease. The data suggest that for
      patients with locally advanced gastric or GEJ cancer, systemic induction therapy, curative
      surgery with high Ro resection rates, and IP adjuvant therapy, has acceptable toxicity and
      encouraging survival outcome. The Medical Research Council Adjuvant Gastric Infusional
      Chemotherapy (MAGIC) trial has also shown that perioperative chemotherapy - chemotherapy
      given both before and after surgery - can provide a significant survival benefit.

      The investigators hypothesize that adjuvant intraperitoneal salvage of cancer micrometastatic
      residues after surgery contributes to disease-free survival. The goal of this trial is to
      determine whether IP Floxuridine, added to adjuvant postoperative chemotherapy, prolongs
      patient's survival. This will be tested during the randomized open-label trial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to slow accrual
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With One-year Recurrence-free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>This is defined as the patients who did not have recurrence of cancer at 1 year since the start of induction chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate; Toxicity; Evaluation of Sites of Relapse of Failing Patients</measure>
    <time_frame>every 4 months for the first 2 years, every 6 months for years 3 and 4, then every 12 months for up to 10 years</time_frame>
    <description>Secondary outcome measure was not analyzed as study was terminated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>A-with IP Floxuridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment:
Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.
Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.
Randomization
Surgery.
Postoperative IP treatment:
Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once
Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-Without IP Floxuridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Same as Arm A except no postoperative IP treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>A-with IP Floxuridine</arm_group_label>
    <arm_group_label>B-Without IP Floxuridine</arm_group_label>
    <other_name>CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>A-with IP Floxuridine</arm_group_label>
    <arm_group_label>B-Without IP Floxuridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <arm_group_label>A-with IP Floxuridine</arm_group_label>
    <arm_group_label>B-Without IP Floxuridine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine</intervention_name>
    <arm_group_label>A-with IP Floxuridine</arm_group_label>
    <other_name>FUDR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>A-with IP Floxuridine</arm_group_label>
    <arm_group_label>B-Without IP Floxuridine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Only untreated patients with histologically documented gastric/GEJ adenocarcinoma,
             clinical American Joint Committee on Cancer (AJCC) stage grouping (11) IB-IV (Mo) by
             CT scan and laparoscopy/endoscopic ultrasound, are eligible. Excluded are patients in
             need of urgent surgery for gastro-intestinal obstruction, perforation or hemorrhage.

          -  Both men and women &gt;= 18 years of age with Eastern Cooperative Oncology Group (ECOG)
             performance status 0-2, members of any ethnic group and minorities.

          -  Patients without another invasive malignancy, with adequately treated basal cell or
             squamous cell skin cancer, free for 5 years or more of in-situ cervix cancer or other
             in-situ cancer.

          -  Since immune deficiency increases the risk of terminal infections when aggravated by
             bone marrow suppressive therapy, patients must be without active or uncontrolled
             infection including HIV.

          -  Patients without psychiatric disorders that may interfere with their consent and/or
             with protocol follow-up.

          -  An adequate bone-marrow reserve (absolute neutrophil count &gt;= 1,500/ mmL, thrombocytes
             &gt;= 100,000 mmL, hemoglobin &gt;= 9 gm/dL).

          -  Preserved liver and renal function (total serum bilirubin &lt;2 mg/dL, SGOT/SGPT =&lt; 3x
             the upper limit of normal, alkaline phosphatase =&lt; 3x the upper limit of normal, blood
             urea nitrogen (BUN) =&lt; 30 mg/dL, serum creatinine concentration &lt;1.5 mg/dL and
             creatinine clearance &gt;= 50 mL/min) are required. Creatinine clearance should be
             normalized for 1.73 M^2 BSA. The prothrombin time, activated partial thromboplastin
             time, and thrombin time should be within the range of normal values.

          -  Since chemotherapeutic agents to be used are known or suspected to be teratogenic or
             with other adverse effects, women must not be pregnant or breast-feeding. All females
             of childbearing potential must have a blood test or urine study within 2 weeks prior
             to registration to rule out pregnancy. All patients of reproductive age may not
             participate unless they agree to use an effective medically acceptable contraceptive
             method.

          -  Patients without diagnosed Gilbert's disease and bilirubin level &gt;= 2.0 mg/dL, as
             these patients may have excessive CPT-11 toxicity.

          -  No prior severe reaction to fluoropyrimidine therapy or known hypersensitivity to
             5-fluorouracil. Capecitabine (Xeloda) is contraindicated in patients with severe renal
             impairment, i.e., creatinine clearance below 30 mL/min, determined by Cockcroft-Gault
             equation shown on page 15 under (i) Renal impairment. In patients with moderate renal
             impairment (creatinine clearance 30-50 mL/min), which develops during the course of
             adjuvant treatment with Capecitabine, the drug is decreased to 75% of the starting
             dose.

          -  Patients should be without any severe concurrent disease, such as cardiac condition
             not responding to medication, myocardial infarction within the last 12 months, active
             infection or uncontrolled pulmonary disease, or any other disease which in judgment of
             the investigator would make the patient inappropriate for entry into this study.

          -  Patients who signed written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Muggia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <results_first_submitted>November 9, 2012</results_first_submitted>
  <results_first_submitted_qc>November 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2012</results_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>gastroesophageal junction</keyword>
  <keyword>stomach cancer</keyword>
  <keyword>intraperitoneal infusion</keyword>
  <keyword>capecitabine</keyword>
  <keyword>irinotecan</keyword>
  <keyword>cisplatin</keyword>
  <keyword>floxuridine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between March 2008 and May 2010 eight patient were enrolled to the study from New York University Langone Medical Center and University of South California Cancer Center.</recruitment_details>
      <pre_assignment_details>Patients were randomized to Arm A or Arm B after the response evaluation of the induction treatment. One patient was not randomized due to progression of disease before surgery and was taken off the protocol treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A-with IP Floxuridine</title>
          <description>Induction treatment:
Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.
Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.
Randomization
Surgery.
Postoperative IP treatment:
Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once
Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral</description>
        </group>
        <group group_id="P2">
          <title>B-Without IP Floxuridine</title>
          <description>Same as Arm A except no postoperative IP treatment.</description>
        </group>
        <group group_id="P3">
          <title>Induction Treartment Only</title>
          <description>This is not a treatment cohort specified in the protocol. The patient in this group was not randomized to Arm A or Arm B due to disease progression before surgery and was taken off the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A-with IP Floxuridine</title>
          <description>Induction treatment:
Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.
Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.
Randomization
Surgery.
Postoperative IP treatment:
Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once
Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral</description>
        </group>
        <group group_id="B2">
          <title>B-Without IP Floxuridine</title>
          <description>Same as Arm A except no postoperative IP treatment.</description>
        </group>
        <group group_id="B3">
          <title>Induction Treatment Only</title>
          <description>This is not a treatment cohort specified in the protocol. The patient in this group was not randomized to Arm A or Arm B due to disease progression before surgery and was taken off the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="12.8"/>
                    <measurement group_id="B2" value="54.3" spread="3.2"/>
                    <measurement group_id="B3" value="60" spread="0"/>
                    <measurement group_id="B4" value="54.8" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With One-year Recurrence-free Survival</title>
        <description>This is defined as the patients who did not have recurrence of cancer at 1 year since the start of induction chemotherapy.</description>
        <time_frame>1 year</time_frame>
        <population>Based on intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>A-with IP Floxuridine</title>
            <description>Induction treatment:
Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.
Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.
Randomization
Surgery.
Postoperative IP treatment:
Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once
Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral</description>
          </group>
          <group group_id="O2">
            <title>B-Without IP Floxuridine</title>
            <description>Same as Arm A except no postoperative IP treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With One-year Recurrence-free Survival</title>
          <description>This is defined as the patients who did not have recurrence of cancer at 1 year since the start of induction chemotherapy.</description>
          <population>Based on intent-to-treat population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Rate; Toxicity; Evaluation of Sites of Relapse of Failing Patients</title>
        <description>Secondary outcome measure was not analyzed as study was terminated</description>
        <time_frame>every 4 months for the first 2 years, every 6 months for years 3 and 4, then every 12 months for up to 10 years</time_frame>
        <population>Secondary outcome measure was not analyzed as study was terminated</population>
        <group_list>
          <group group_id="O1">
            <title>A-with IP Floxuridine</title>
            <description>Induction treatment:
Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.
Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.
Randomization
Surgery.
Postoperative IP treatment:
Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once
Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral</description>
          </group>
          <group group_id="O2">
            <title>B-Without IP Floxuridine</title>
            <description>Same as Arm A except no postoperative IP treatment.</description>
          </group>
          <group group_id="O3">
            <title>Induction Treatment Only</title>
            <description>This is not a treatment cohort specified in the protocol. The patient in this group was not randomized to Arm A or Arm B due to disease progression before surgery and was taken off the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rate; Toxicity; Evaluation of Sites of Relapse of Failing Patients</title>
          <description>Secondary outcome measure was not analyzed as study was terminated</description>
          <population>Secondary outcome measure was not analyzed as study was terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were followed during the whole treatment phase, about 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A-with IP Floxuridine</title>
          <description>Induction treatment:
Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.
Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.
Randomization
Surgery.
Postoperative IP treatment:
Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once
Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral</description>
        </group>
        <group group_id="E2">
          <title>B-Without IP Floxuridine</title>
          <description>Same as Arm A except no postoperative IP treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/Granulocytes (Anc/Agc)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection With Normal Anc Or Grade 1 Or 2 Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Other (Specify, __)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neutrophils/Granulocytes (Anc/Agc)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Distension/Bloating, Abdominal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysphagia (Difficulty Swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Taste Alteration (Dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (Asthenia, Lethargy, Malaise)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alt, Sgpt (Serum Glutamic Pyruvic Transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ast, Sgot(Serum Glutamic Oxaloacetic Transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose, Serum-High (Hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mood Alteration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neurology - Other (Specify, __)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neuropathy: Sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair Loss/Alopecia (Scalp Or Body)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Franco Muggia, MD</name_or_title>
      <organization>NYU Cancer Institute</organization>
      <phone>212-263-6485</phone>
      <email>franco.muggia@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

